Sitravatinib - Mirati Therapeutics

Drug Profile

Sitravatinib - Mirati Therapeutics

Alternative Names: MG-516; MG91516; MGCD-0516; MGCD-516

Latest Information Update: 02 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MethylGene
  • Developer Columbia University; Mirati Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Eph family receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-mer inhibitors; Receptor protein-tyrosine kinase antagonists; RON protein inhibitors; TIE 2 receptor antagonists; Tropomyosin-related kinase antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liposarcoma; Non-small cell lung cancer; Soft tissue sarcoma
  • Phase I/II Renal cell carcinoma
  • No development reported Solid tumours

Most Recent Events

  • 06 Aug 2018 Mirati Therapeutics plans a phase II trial for Urogenital cancer (PO) (NCT03606174)
  • 02 Jul 2018 Mirati Therapeutics plans the early phase I SNOW trial for Squamous-cell-cancer in Canada , (NCT03575598)
  • 31 May 2018 BeiGene plans a clinical trial in Renal cell carcinoma (Combination therapy, Metastatic disease) in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top